American Regent introduces estradiol valerate injection

Print Friendly, PDF & Email

SHIRLEY, N.Y. — American Regent announces the introduction and availability of estradiol valerate injection, USP – AO Rated and therapeutically equivalent to Delestrogen.

Estradiol valerate injection is indicated in the:

  • Treatment of moderate to severe vasomotor symptoms associated with the menopause.
  • Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
  • Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.
  • Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).

“We are proud to add Estradiol Valerate Injection to our robust product line of products that are manufactured in America. We are also pleased to provide patients with another treatment option from American Regent,” stated Delestrogen, vice president, chief commercial and strategic officer at American Regent.


Comments are closed.